Abstract
O varian cancer is the sixth most common form of cancer worldwide and has the highest mortality rate of all gynaecological cancers. According to the results of a recent European cost-effectiveness analysis, healthcare decision-makers should consider combination therapy with paclitaxel plus cisplatin as a cost-effective therapeutic option for the first-line management of advanced ovarian cancer. 1 The results of this analysis were presented at the First European Conference on the Economics of Cancer [ Brussels, Belgium; November 1997 ], convened by the European Organisation for Research and Treatment of Cancer (EORTC).
This is a preview of subscription content, log in via an institution to check access.
Additional information
1. Berger K, et al. Cost-effectiveness analysis of paclitaxel and cisplatinum versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer - a European perspective. European Journal of Cancer: Part A 33 (Suppl. 9): 1, Nov 1997 [abstract]
Rights and permissions
About this article
Cite this article
Cameron, A. Consider paclitaxel plus cisplatin for advanced ovarian cancer. Pharmacoecon. Outcomes News 149, 3 (1998). https://doi.org/10.1007/BF03277392
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03277392